Spero Therapeutics (SPRO) Net Margin (2017 - 2026)
Spero Therapeutics (SPRO) reported Net Margin of -2791.86% for Q1 2026, down 2555.22 percentage points from -236.64% a year earlier and down 2868.25 percentage points from the prior quarter.
Powered by 
Analysis
Spero Therapeutics (SPRO) Net Margin (2017 - 2026) Analysis & Trends
For FY2025, Spero Therapeutics posted Net Margin of 12.87%, up 155.86 percentage points from FY2024.
- Net Margin has a five-year change of +851.89 percentage points (FY2020 to FY2025).
- By year, Net Margin came in at -142.99% in FY2024 (-164.96 pp), 21.98% in FY2023 (+108.72 pp), -86.74% in FY2022 (+405.15 pp) and -491.89% in FY2021 (+347.12 pp).
- The Q1 2026 figure ranks as the lowest quarterly Net Margin since Q4 2019.
- Year over year, Net Margin gained in three of the last eight quarters, with an average year-over-year change of -293.10 percentage points.
- The high point for year-over-year Net Margin in five years was Q4 2022 (a gain of 1123.63 percentage points); the low point was Q1 2026 (a drop of 2555.22 percentage points).
- Per Business Quant data, the three quarters before Q1 2026 came in at 76.39% (Q4 2025), -135.98% (Q3 2025) and -11.98% (Q2 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn | 30.88% |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn | 21.86% |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn | 21.27% |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn | -8.04% |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn | 22.65% |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn | 16.30% |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn | 23.62% |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn | -134.51% |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn | -1.65% |
| 10 | Spero Therapeutics | 68.40 Mn | -127.38 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | -2,791.86% |
| Dec 31, 2025 | 76.39% |
| Sep 30, 2025 | -135.98% |
| Jun 30, 2025 | -11.98% |
| Mar 31, 2025 | -236.64% |
| Dec 31, 2024 | -138.93% |
| Sep 30, 2024 | -127.31% |
| Jun 30, 2024 | -175.54% |
| Mar 31, 2024 | -137.05% |
| Dec 31, 2023 | 69.65% |
| Sep 30, 2023 | -12.58% |
| Jun 30, 2023 | -438.66% |
| Mar 31, 2023 | -641.18% |
| Dec 31, 2022 | 56.43% |
| Sep 30, 2022 | -582.00% |
| Jun 30, 2022 | -1,439.14% |
| Mar 31, 2022 | -1,586.71% |
| Dec 31, 2021 | -1,067.20% |
| Sep 30, 2021 | -735.02% |
| Jun 30, 2021 | -360.76% |
API Access
Spero Therapeutics Net Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-margin&ticker=SPRO&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-margin", "ticker": "SPRO", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-margin&ticker=SPRO&period=max&api_key=YOUR_API_KEY");
const data = await res.json();